Introduction
Ovarian cancer is a very common malignancy, with an estimated incidence of 21,880 new cases in 2010, as well as the most fatal gynecological malignancy and fifth leading cause of cancer-related mortality in women, with an estimated 13,850 deaths annually in the United States 1 . When possible, the best outcomes for advanced disease are obtained utilizing a combination of surgery and neoadjuvant or adjuvant chemotherapy. Initial response rates to chemotherapy vary from 60-80%, however, most patients with persistent or recurrent disease requiring chronic chemotherapy will develop drug resistance and eventually experience progression of disease 2 . For these patients, new therapeutic strategies are needed.
TRAIL (TNF-related apoptosis-inducing ligand) is a member of the tumor necrosis factor super family of cell death-inducing ligands 3 . TRAIL can induce programmed cell death or apoptosis in a variety of tumor cell lines and not in normal or non-transformed cells 4 . TRAIL induces apoptosis by activating the extrinsic apoptosis pathway by interacting with the death receptors (DRs), DR4 and DR5. TRAIL binding to
DRs induces receptor oligomerization resulting in the formation of a death inducing signaling complex (DISC), which contains the Fas associated death domain (FADD) and
pro-caspase-8 and leads to activation of caspase-8. Activation of caspase-8 activates caspase-3 and induces apoptosis 5 . Alternatively, activated caspase-8 can cleave Bid, a pro-apoptotic protein, resulting in truncated Bid (tBid) that can translocate to mitochondria and initiate intrinsic apoptosis [6] [7] [8] .
While higher levels of expression of DRs can render cells more susceptible to TRAIL induced apoptosis, increased levels of expression of decoy death receptors (DcR1 and DcR2) and anti-apoptotic proteins ( c-FLIP, x-IAP, Survivin, BCL2 , MCL1
and MADD) can confer significant resistance to TRAIL-induced apoptosis [9] [10] [11] [12] [13] [14] [15] . The two decoy receptors DcR1 and DcR2 lack a functional death domain and compete with DR4
and DR5 for cell surface TRAIL binding but cannot transmit the apoptotic signal 9 . The anti-apoptotic protein c-FLIP, an inhibitor of death ligand induced apoptosis, comes in two isoforms --a long form (c-FLIP L ) and a short form (c-FLIP S ). The c-FLIP L , a 55-kDa protein, contains two DEDs and a caspase-like domain, whereas c-FLIP S , a 26-kDa protein consists only of two DEDs 10 . Both isoforms are recruited to the DISC via binding to FADD, and they prevent procaspase-8 recruitment and thus block DR-mediated apoptosis 16, 17 . The c-FLIP L is over expressed in a number of different tumors and is often associated with TRAIL resistance 11, 12 . The Bcl2 family proteins (Bcl2 and MCL1) act as mitochondrial intracellular checkpoints [12] [13] [14] and resist apoptosis. Execution of the apoptotic program is also controlled by inhibitor of apoptosis proteins (IAP, x-IAP and Survivin), which can selectively bind and inhibit caspases-3, -7, and -9, thereby prevent cell death in response to multiple stimuli 15 .
We have previously identified and characterized MADD as a TRAIL resistance factor. MADD is an isoform of the IG20 (Insulinoma-Glucagonoma 20) gene 18 and is expressed at very low levels in most healthy tissues but is expressed at significantly higher levels in many human tumors and tumor cell lines 15, 18, 19 . Knockdown of MADD expression results in enhanced spontaneous and TRAIL-induced apoptosis in cells derived from cervical cancer, neuroblastoma and thyroid cancer 20, 21, 22 . Further, expression of exogenous MADD, and not other IG20 splice variants, in the absence of all endogenous isoforms can rescue these cells from undergoing apoptosis 20, 23 . These findings indicated that only MADD isoform of the IG20 gene can promote cancer cell survival 20, 23 The current study was initiated to determine if ovarian cancer tissues and cells express MADD at higher levels and whether it contributes to TRAIL resistance in ovarian cancer cells.
Materials and methods

Cell culture
OVCA429, OVCAR-3, CAOV-3 and SKOV-3 ovarian cancer cells were purchased from ATCC and cultured according their instructions. Briefly, OVCA429 and SKOV-3 cells were cultured in RPMI 1640 (Invitrogen, CA, USA) supplemented with 10% fetal bovine serum (FBS). OVCAR-3 cells were cultured in RPMI 1640 containing 20% FBS plus 0.01mg/ml bovine insulin. CAOV-3 cells were cultured in DMEM (Invitrogen, CA, USA) with 10% FBS. Culture media were also supplemented with 100 units/ml of penicillin, and 100 µg/ml of streptomycin. The cell lines were maintained at 37 o C in a humidified chamber with 5% CO 2 .
Antibodies
Antibody to FLIP L (NF6) was purchased from Enzo life science Inc. (Farmingdale, NY).
The preparation of anti-MADD exon 13L (anti-13L) specific antibodies has been reported earlier 24 . The goat anti-mouse IgG1 peroxidase-conjugated secondary antibody was obtained from Caltag Laboratories (Burlingame, CA) and the anti-rabbit peroxidaseconjugated polyclonal secondary antibody was purchased from GE Healthcare (Piscataway, NJ). Antibodies against DR4, DR5, DcR1 and DcR2 were purchased from Ebioscience (San Diego, CA). 20, 21 . The siRNA targeting c-FLIP was designed using OligoEngine Workstation 2 and purchased from OligoEngine, Inc. (Seattle, WA). These siRNAs were screened in OVCA429 cells and the most efficient one was used to construct the cFLIP-shRNA lentivirus.
Tissue samples and RNA preparation
Plasmid construction
The siRNAs were cloned into the pSUPER vector using BgI II and HindIII sites 25 
Preparation of Lentivirus stocks
Lentivirus stocks were prepared as described previously 25 . Briefly, sub-confluent 293FT cells grown in 100 mm plates were co-transfected with 10.8 µg of lentivirus vector (containing either SCR, MID or cFLIP shRNA), 1 µg pcRev, 1 µg of pcTat and 0.5 µg of pHIT/G using calcium phosphate. Culture medium was replaced after 16 h, and the supernatant was harvested at 40 h and filtered using a 0.22 mm filter. The optimal viral titer for each cell type was determined as the least amount of viral supernatant required to transduce at least 80% of target cells without apparent cytotoxicity. Ribosomal RNA control reagents (Applied Biosystems, Carlsbad, CA) were used for amplifying the endogenous control. Delta-delta CT method was used to calculate the relative expression levels of tested genes versus to 18s rRNA. Data were analyzed using q-gene program 26 .
Quantitative Real-Time PCR
Reverse transcription-polymerase chain reaction
We TCT GAC TCC GAA CCT AC-3` and 5`-GCG GTT CAG CTT GCT CAG GAC-3`, respectively) were used. GAPDH was used as a loading control was amplified using.
GAPDH primers that have been previously published 27 . The PCR products were then separated on a 5% polyacrylamide gel. 
Flow cytometry to detect death (DRs) and decoy (DcRs) receptors
Cell surface expression of death/decoy receptors was evaluated by flow cytometry as previously described 27 
Western Blot Analysis
Different shRNA-expressing, lentivirus-transduced ovarian cancer cells were trypsinized and washed with phosphate-buffered saline and lysed at 0 °C for 30 min in a lysis buffer (20 mM Hepes, pH 7.4, 2 mM EGTA, 420mM NaCL, 1% Triton X-100, 10% glycerol, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml leupeptin, 10 µ/ml aprotinin, 1 mM Na 3 VO 4 , and 5 mM NaF). The protein content was determined using a Proteins were detected using an enhanced chemiluminescence plus western blotting detection system (Amersham, UK). HRP labeled anti-beta-actin (Sigma-Aldrich)
antibodies were used to detect beta-actin, which served as a loading control.
Statistical analysis
All results are expressed as mean ± SE. Student's t test was used to determine P values using Microsoft Excel Software (version 2003). P-values less than or equal to 0.05 were considered significant.
Results
Expression of IG20/MADD in ovarian cancer tissues and cell lines
Relative to normal ovarian tissues (samples 2-9), expression of the IG20 gene was higher in four of seven malignant ovarian cancer tissues (samples [11] [12] [13] [14] [15] [16] [17] [18] [19] and in most of the serous-type ovarian cancer cell lines (Fig-1A and Table- MADD expression in ovarian cancer cell lines was confirmed by immunofluorescence staining using an antibody generated against a peptide encoded by exon 13L
(expressed only in the IG20pa and MADD isoforms of the IG20 gene) (Fig 1c) . Since the levels of expression of IG20pa are minimal as indicated by RT-PCR (Fig.1B) , the staining noted is mostly due to antibody binding to the MADD isoform (Fig.1C) .
TRAIL-induced apoptosis of ovarian cancer cells
Since MADD was expressed at higher levels in ovarian cancer cells and it can confer resistance to TRAIL-induced apoptosis, we investigated the susceptibility of ovarian cancer cell lines to TRAIL treatment (Fig-2) . About twenty-five percent of OVCA429 and OVCAR-3 cells were sensitive to TRAIL treatment compared to 4% of CAOV-3 and 10%
of SKOV-3 cells at a concentration of 100ng/ml of TRAIL treatment for 4 hours. Next, to test if MADD contributed to the observed resistance to TRAIL, we measured TRAILinduced apoptosis upon MADD knockdown.
Effects of MADD knockdown on TRAIL-induced apoptosis
Ovarian cancer cells were transduced with lentiviruses capable of co-expressing GFP and specific shRNAs. The transduction efficiency was monitored through GFP expression and was greater than 85% (data not shown). Seventy-two hours following viral transduction the cells were harvested, RNA extracted and subjected to RT-PCR using F1/B1 primers and amplified cDNA products were separated by polyacrylamide gel electrophoresis using a 5% gel and visualized. IG20 transcripts were essentially absent by 72 h post-transduction in cells transduced with Mid-shRNA (that can knockdown all isoforms of IG20) but not in cells that were left untreated or treated with control ScrshRNA (Fig 3a) . Similarly, MADD protein expression, as detected by western blotting, was also reduced upon knock down with Mid-shRNA (Fig-3B ).
To test for the sensitivity of cells to TRAIL-induced apoptosis in the absence of (Fig-3C ). In contrast, MADD knockdown had no effect on TRAIL induced apoptosis in OVCA-429 and SKOV3 cells.
Expression of death (DRs), decoy (DcRs) receptors, and anti-apoptotic factors in ovarian cancer cell lines
Since the levels of expression of DRs or DcRs affect cell sensitivity to TRAIL-induced apoptosis, we evaluated the cell surface expression of these receptors. We found that DR4 expression was minimal while DR5 was readily detectable in all 4 cell lines.
Examination of DcR1 or DcR2 expression revealed little or no difference between different cell lines tested (Fig-4A ). This suggested that factors other than loss of DR or enhanced DcR expression may be involved in conferring resistance to TRAIL-induced apoptosis in OVCA-429 and SKOV3 cells.
Therefore, we investigated levels of expression of c-FLIP, x-IAP, Survivin, Bcl-2 and MCL2 using q-RT-PCR (Supplementary Fig.1 and Supplementary Fig.2 ). Survivin ( Supplementary Fig.1B ) and c-FLIP (Fig.4B ) are expressed at higher levels in malignant tissues and ovarian cancer cell lines compared to the normal tissues.
Combined knock down of MADD and c-FLIP can enhance TRAIL-induced apoptosis in SKOV-3 cells
Since shown that IG20 appears to play a critical role.
Our early studies showed that MADD is highly expressed in different cancers and cancer cell lines and can confer TRAIL resistance 20, 22 , therefore, we investigated MADD expression and function in ovarian cancer tissues and found that it was expressed at higher levels in tissues and cell lines. Specifically, we found that MADD and DENN-SV were expressed in all ovarian cancer cell lines tested and showed MADD protein expression in these cells using an antibody that specifically reacts only with an amino acid sequence in IG20pa and MADD isoforms (Fig.1) . This is of significance because our earlier studies demonstrated that the MADD splice variant of the IG20 gene is a cancer cell pro-survival factor 20, 22 .
The IG20 gene can encode 6 different isoforms, namely IG20pa, MADD, DENN-SV, IG20-SV2, KIAA0358 and IG20-AV4 . The KIAA0358 and IG20-SV4 isoforms are enriched only in select neuronal cells 21 and thus are not pertinent to this study. Of the other 4 isoforms, the IG20pa and the IG20-SV2 may be expressed at very low levels or may not be expressed, and thus are not required for critical cellular functions including cell survival. However, the MADD and the DENN-SV isoforms are ubiquitously expressed in most normal tissues at very low levels but are expressed at much higher levels in cancer cells and tissues 18, 22, 44 . Selective knockdown of MADD using exon 13 specific siRNA renders cancer cells susceptible to spontaneous as well as induced apoptosis 23 . Moreover, re-expression of siRNA resistant MADD and not the other isoforms of the IG20 gene, in the absence of all endogenous isoforms due to siRNA mediated knockdown, can confer resistance to spontaneous as well as TRAIL-induced apoptosis in a variety of cancer cells 22, 23 . Therefore, we tested the sensitivity of ovarian cancer cells to TRAIL treatment in the presence or absence of MADD expression.
We selected four epithelial serous subtype ovarian cancer cell lines, OVCA-429, OVCAR-3, CAOV-3 and SKOV-3 because epithelial serous type is a major histological type of ovarian cancer 45 and is usually diagnosed at an advanced stage of the disease.
These types of tumors often develop drug resistance and therefore, there is a significant need for newer modalities of treatment for ovarian cancer.
We found that while OVCA-429 and OVCAR-3 were moderately sensitive, CAOV-3 and SKOV-3 cells were less sensitive to TRAIL treatment (Fig-2) . To evaluate the potential contribution of MADD to the observed TRAIL resistance, we transduced these cells with SCR or MID-shRNA carrying lentivirus, MID-shRNA effectively downmodulated the mRNA and protein expression (Fig.3A and -3B ). Although downmodulation of MADD resulted in spontaneous apoptosis of all four types of cells (Fig.3C) , it further sensitized only CAOV-3 cells to TRAIL induced apoptosis (Fig.3C ). These data suggested that while MADD may not contribute to TRAIL resistance in OVCA-429 and OVCAR-3 cells, it could do so in CAOV-3 cells. These data also indicated that other factors may be contributing to the TRAIL resistance of SKOV-3 cells.
Known inhibitors that can block TRAIL-induced apoptosis include expression of lower levels of DRs or higher levels of DcRs, or anti-apoptotic factors such as cFLIP, x-IAP, Survivin, Bcl-2 and MCL1 9-15, 17,30 . Therefore, we tested for the levels of expression of these molecules. Our results showed little or no difference in the levels of expression of DRs and DcRs (Fig.4A ) and indicated that factors other than the levels of expression of these molecules were most likely responsible for the differential susceptibility to TRAIL.
We found much higher levels of c-FLIP and survivin transcripts in all four cell lines and some of the malignant tissues relative to normal tissues. However, the levels of transcripts for XIAP, Bcl2 and MCL1 were comparable in both normal and tumor tissues with the exception of few ovarian cancer tissues which expressed much higher levels (Fig.4B) . Survivin levels were comparable in all four cell lines and suggested that it may not be a critical TRAIL resistance factor in these cells, however, c-FLIP levels varied between the cell lines and was the highest in SKOV-3 cells. Detection of IG20 gene expression in ovarian cancer tissues (supplementary Table-1) and cell lines by qRT-PCR. One µg of total RNA was extracted from ovarian cancer tissues or cell lines, and subjected to qRT-PCR by using TaqMan one-step RT-PCR Master Mix Kit (Applied Biosystems, CA, USA). Primer set and probe # 1 listed in supplementary Table-3 Representative data are shown from three independent experiments. B. Effect of c-FLIP and IG20 knockdown on TRAIL-induced apoptosis in TRAIL resistant SKOV-3 cell lines.
Data Summarized from three independent experiments are shown.
Supplementary Figure legends
